Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
Authors
Califano, RaffaeleHochmair, MJ
Gridelli, C
Delmonte, A
Campelo, MRG
Bearz, A
Griesinger, F
Morabito, A
Felip, E
Ghosh, S
Tiseo, M
Haney, J
Kerstein, D
Popat, S
Camidge, DR
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, ManchesterIssue Date
2019
Metadata
Show full item recordCitation
Califano R, Hochmair MJ, Gridelli C, Delmonte A, Garcia Campelo MR, Bearz A, et al. 106O Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Ann Oncol. 2019;30(Supplement_2):41.Journal
Annals of OncologyDOI
10.1093/annonc/mdz063.004Additional Links
https://dx.doi.org/10.1093/annonc/mdz063.004Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz063.004